Galcanezumab-gnlm (Emgality) coverage
Customize your policy alerts
Sign up for meridian Policy MDN.CP.PHAR.404 alerts
Get alerted when Policy MDN.CP.PHAR.404 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, prior authorization, and coverage criteria for Emgality (galcanezumab-gnlm) for migraine prophylaxis and episodic cluster headache for Meridian Health Plan Medicaid line of business.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met for migraine prophylaxis:
Preserves nested concurrent-Botox conditions.
Initial Therapy - Episodic Cluster Headache
Covered when ALL of the following are met for episodic cluster headache:
Approval duration: 3 months.
Continuation Therapy - Migraine
Continued coverage when ALL of the following are met for migraine prophylaxis:
Approval duration: 3 months.
Continuation Therapy - Episodic Cluster
Continued coverage when ALL of the following are met for episodic cluster headache:
Approval duration: 6 months (up to 12 months per cluster period).
Indication-specific dosing and coverage
Covered when dosing and indication align with trial evidence and FDA-approved dosing:
Based on pivotal trials and FDA-approved dosing.
Per pivotal episodic cluster headache dosing regimen.
Non‑FDA‑approved indications that are not specifically addressed in this policy are excluded from coverage unless the provider submits sufficient documentation of efficacy and safety consistent with Meridian’s off‑label use policy (see CP.PMN.53) or other applicable evidence‑of‑coverage documents.
Clinical trial data do not support use of Emgality for chronic cluster headache. Emgality failed to meet the primary endpoint in the Phase 3 chronic cluster headache trial, and efficacy has been demonstrated only for episodic cluster headache.
Coverage is not authorized for chronic cluster headaches.
Clinical trial evidence and FDA‑approved dosing support a monthly maintenance dose of 120 mg for migraine prophylaxis; randomized trials comparing 120 mg versus 240 mg did not show clinically meaningful additional benefit with higher maintenance dosing, therefore use of a maintenance dose greater than 120 mg monthly for migraine prophylaxis is not supported.
Initial Therapy Rules
Initial therapy rules
Initial approval criteria for covered indications:
Approval duration: 3 months.
Approval duration: 3 months.
Initial therapy
Initial dosing regimens per indication:
Trials used 120 mg and 240 mg regimens; 120 mg is FDA-approved maintenance dose.
300 mg/month is the maximum episodic cluster dosing.
Continuation Therapy Rules
Continuation therapy rules
Continuation therapy requirements:
Approval duration typically per policy (see continuation section).
Approval duration: 6 months (up to 12 months per cluster period).
Continuation therapy
Maintenance dosing after initiation:
FDA-approved maintenance dose is 120 mg monthly; higher maintenance dosing showed no additional clinical benefit in trials.
Provider Actions & Prior Authorization
Obtain prior authorization with full criteria documentation
Prior authorization is required. Submit documentation showing the member meets all approval criteria, including diagnosis, age ≥18, required prior therapy failures, and dosing within the policy limits (loading dose ≤240 mg once; maintenance ≤120 mg once monthly for migraine; ≤300 mg once monthly for episodic cluster headache).
- Approval durations: initial approvals up to 3 months (initial therapy) and continuation durations per policy sections.
- Do not request concurrent use with other injectable or oral CGRP inhibitors or Botox unless the special concurrent-use criteria are documented.
Billing note — J3490 implies PA is required
When billing, note the policy references HCPCS code J3490 (unclassified drugs); prior authorization should be obtained per Meridian procedures before billing under J3490.
- Codes referenced are informational and inclusion/exclusion does not guarantee coverage; confirm current coding guidance prior to claim submission.
Document failure of ≥2 oral preventives (8 weeks each)
For migraine prophylaxis, document failure of at least two oral preventive therapies from different therapeutic classes, each tried for at least 8 weeks, unless contraindicated or intolerant.
- Acceptable classes include anticonvulsants (e.g., divalproex, topiramate), beta-blockers (e.g., metoprolol, propranolol), and antidepressants (e.g., amitriptyline, venlafaxine).
- Therapy failures must be from different classes as listed in the therapeutic alternatives.
Step therapy — evidence noted but no extra mandatory steps
The policy discusses trial evidence and comparative results but does not impose any additional mandatory step therapy beyond the documented requirement for failure of two oral preventive agents.
- Evidence hierarchy and trial design considerations are noted in appendices but do not change the stated prior therapy requirement.
Submit office notes and clinical records with PA request
Providers must submit supporting clinical documentation such as office chart notes, lab results, or other clinical information demonstrating that the member has met all approval criteria.
- Include records of prior medication trials, dates and durations of therapy, and any notes on contraindications or intolerances.
Document ICHD-3 diagnosis, migraine days, and dosing regimen
Document the diagnosis using ICHD-3 criteria (migraine or cluster headache), record migraine days per trial definitions, and record the dosing regimen used (loading and maintenance doses).
- Migraine day definition: headache ≥2 consecutive hours meeting ICHD-3 migraine/probable migraine criteria or any-duration headache treated with migraine-specific medications.
- Specify if loading dose (240 mg once) was used and the maintenance dose requested (120 mg monthly for migraine; 300 mg monthly for episodic cluster headache).
Denial risk if documentation or dosing limits not met
Requests may be denied if documentation does not support the required diagnosis, prior treatment failures, age criteria, concurrent use restrictions, or if dosing exceeds the policy limits.
- Concurrent prescribing with other CGRP inhibitors or Botox without meeting the policy's concurrent-use criteria is a denial trigger.
- Dose requests above 120 mg monthly for migraine or above 300 mg monthly for episodic cluster headache may be denied.
Coding listed does not guarantee coverage — confirm before claim submission
Inclusion or exclusion of HCPCS or other codes in this policy does not guarantee coverage; providers must reference the most up-to-date professional coding guidance before submitting claims.
- Codes in the policy are informational only; confirm appropriate codes and billing practices with current coding resources.
Coding and Definitions
| J3490 | Unclassified drugs |
Step Therapy Evidence & Requirements
| Requirement | Details |
|---|---|
| Trials must be from different therapeutic classes (examples) | Anticonvulsants (e.g., divalproex sodium, topiramate); Beta-blockers (e.g., metoprolol, propranolol, timolol); Antidepressants/tricyclics (e.g., amitriptyline, venlafaxine) |
| Failure duration per agent | Each oral preventive must be tried for at least 8 weeks unless contraindicated or significant adverse effects occur |
| Aggregate requirement | Failure of at least 2 oral migraine preventive therapies from different therapeutic classes is required prior to Emgality for migraine prophylaxis |
| Topic | Policy notes / implications |
|---|---|
| Mandatory step therapy specified? | No mandatory step therapy is specified in the cited excerpts; the policy requires failure of at least 2 oral preventive therapies from different classes for migraine (see separate requirement), but Appendix E notes about evidence hierarchy do not impose additional step therapy rules |
| Evidence hierarchy and trial design considerations | Randomized, prospective controlled trials are considered the gold standard; non-randomized prospective trials with substantial subject numbers may be supportive; case reports and chart reviews are generally insufficient |
| Practical implication for prior authorization reviews | Reviewers should rely on documented trial failures of therapies from different classes and consider trial quality per Appendix E when evaluating clinical justification; lack of randomized trial evidence may reduce strength of support but does not alone determine coverage |
Quantity Limits & Dosing
Definitions
Background
Emgality (galcanezumab‑gnlm) is a monoclonal antibody that targets the calcitonin gene‑related peptide (CGRP) pathway and is indicated for preventive treatment of migraine in adults and for treatment of episodic cluster headache in adults. Clinical trials (EVOLVE‑1, EVOLVE‑2, REGAIN) showed a reduction in migraine days with either 120 mg SC once monthly or 240 mg SC once monthly, but no clinically significant advantage of the higher maintenance dose over the FDA‑approved 120 mg once monthly. For episodic cluster headache, efficacy was demonstrated with a regimen of 300 mg once monthly given as three consecutive 100 mg injections at cluster onset and continued monthly for the cluster period.
Site of Care
Product availability and possible home administration
Product is available as single‑dose prefilled pen and syringe for subcutaneous administration and may be administered in appropriate outpatient settings or at home per prescribing information.
- Available presentations: single-dose prefilled pen (120 mg/mL) and single-dose prefilled syringe (100 mg/mL, 120 mg/mL).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.